Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721777 | 0.91 | NPC1 (0.51) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL721057 | 0.89 | MAOB (0.41) | KDM4EALDH1A1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL718632 | 0.88 | NPC1 (0.45) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL719312 | 0.88 | SMN1; SMN2 (0.45) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL717086 | 0.87 | NPC1 (0.46) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL719143 | 0.86 | NPC1 (0.43) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL716349 | 0.85 | KMT2A (0.45) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL719322 | 0.83 | KMT2A (0.43) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL717999 | 0.80 | GCGR (0.47) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL718173 | 0.79 | CASP3 (0.43) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | KDM4E 1907/4885ALDH1A1 504/4885NPC1 902/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | KDM4E 1907/4885ALDH1A1 504/4885NPC1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.